Table 3 Adherence of health practice guidelines (HPGs) to RIGHT checklist items addressing the domains of review and quality assurance, funding, declaration and management of interest, and other information (total number and percentage with 95% confidence intervals (CI) of addressed items)

External review

 16—Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.

1 (3.8, 0.2–21.6)

10 (41.7, 24.5–61.2)

< 0.001

55.35

 17—Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.

1 (3.8, 0.2–21.6)

3 (12.5, 4.0–31.0)

0.260

0.33

 18a—Describe the specific sources of funding for all stages of guideline development.

18 (69.2, 48.1–84.9)

5 (20.8, 9.2–40.5)

< 0.001

122.90

 18b—Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.

2 (7.7, 1.3–26.6)

2 (8.3, 2.3–25.9)

0.933

0.19

 19a—Describe what types of conflicts (financial and non-financial) were relevant to guideline development.

2 (7.7, 1.3–26.6)

22 (91.7, 74.2–97.6)

< 0.001

1.02 × 10⁸

 19b—Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.

1 (3.8, 0.2–21.6)

1 (4.2, 0.7–20.2)

0.954

0.15

 20—Describe where the guideline, its appendices, and other related documents can be accessed.

1 (3.8, 0.2–21.6)

3 (12.5, 4.0–31.0)

0.260

0.33

 21—Describe the gaps in the evidence and/or provide suggestions for future research.

12 (46.2, 27.1–66.3)

23 (95.8, 79.8–99.3)

< 0.001

733.7

 22—Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients’ values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.

1 (3.8, 0.2–21.6)

1 (4.2, 0.7–20.2)

0.954

0.15